Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% Earnings per Share (Diluted) is $-0.01 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 159 Medical Diagnostics & Research companies, Verici Dx ranks better than 84.28% on this metric.
Verici Dx's EPS (Basic) for the
six
months ended in Dec. 2025 was $-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.
Verici Dx's EPS without NRI for the
six
months ended in Dec. 2025 was $-0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.
During the past 3 years, the average EPS without NRIGrowth Rate was 50.30% per year.
During the past 6 years, Verici Dx's highest 3-Year average EPS without NRI Growth Rate was 50.30% per year. The lowest was 23.10% per year. And the median was 36.70% per year.
Verici Dx (OTCPK:VRCDF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Verici Dx Earnings per Share (Diluted) Related Terms
Verici Dx Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Verici Dx's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCDF vs TMO, DHR, IDXX: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Verici Dx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's PE Ratio distribution charts can be found below:
* The bar in red indicates where Verici Dx's PE Ratio falls into.
Verici Dx Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Verici Dx's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.01 mean?
Verici Dx (VRCDF) has a Earnings per Share (Diluted) of $-0.01 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #25 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 15.7%.
Is Verici Dx's Earnings per Share (Diluted) too high?
Verici Dx's current Earnings per Share (Diluted) is $-0.01. Based on the distribution chart, Verici Dx ranks #25 out of 159 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Earnings per Share (Diluted) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #25 out of 159 companies for Earnings per Share (Diluted). This places Verici Dx in the top 16% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Earnings per Share (Diluted) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Earnings per Share (Diluted) of $-0.01. The current Earnings per Share (Diluted) is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Earnings per Share (Diluted) is $-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
